Allergen Immunotherapy (AIT)

"Immune system desensitization" is not a molecule or receptor but rather a therapeutic process or clinical strategy. The term refers to **allergen immunotherapy** (also called desensitisation or hyposensitization), which is used to treat allergies by gradually exposing the immune system to increasing doses of an allergen. This process retrains the immune response so that it becomes less reactive over time, reducing symptoms such as sneezing, itching, and wheezing when exposed to the allergen in daily life[1][2][4]. Immunotherapy can be administered via subcutaneous injections ("allergy shots") or sublingual tablets/drops. It is primarily used for environmental allergies (e.g., pollen, dust mites), food allergies (via oral immunotherapy), and insect venom allergy[1][2][4]. The mechanism involves shifting antibody production and modulating T-cell responses toward tolerance rather than hypersensitivity. While effective for many patients with allergic rhinitis or asthma triggered by known allergens, "immune system desensitization" itself does not refer to a discrete molecular target but rather describes this broader clinical approach. **Key points:** - Not a single molecule/receptor; it is a therapeutic method. - No canonical abbreviation; sometimes referred to as AIT (Allergen Immunotherapy). - Not considered a druggable target like receptors/enzymes. - Commonly confused as a molecular entity due to its name—this is incorrect. If you are seeking information on specific molecules involved in this process—such as IgE receptor (FcεRI), interleukins involved in allergy pathways (e.g., IL‑4, IL‑5), or other immune checkpoints—please specify further so structured data can be provided for those actual targets.

Other names

Immune desensitizationAllergy desensitizationAllergen immunotherapyDesensitisationHyposensitization

Induction of immune tolerance to specific allergens through controlled exposure[1][2][4][5]